ID   Sez627
AC   CVCL_5364
SY   Sez 627; SEZ 627; SEZ627; Sez627(+); Sez.627
DR   RCB; RCB3547
DR   Wikidata; Q54952868
RX   PubMed=3023492;
RX   PubMed=3263317;
RX   PubMed=16242045;
RX   PubMed=32210945;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=Sez627
CC   Population: Japanese.
CC   Characteristics: IL2 dependent.
CC   Transformant: NCBI_TaxID; 11908; Human T-lymphotropic virus 1 (HTLV-1).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C3467; Primary cutaneous T-cell non-Hodgkin lymphoma
DI   ORDO; Orphanet_171901; Primary cutaneous T-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   10Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 13
//
RX   PubMed=3023492; DOI=10.1016/0022-1759(86)90236-X;
RA   Namiuchi S., Kumagai S., Sano H., Yodoi J., Uchiyama T., Ikai K.,
RA   Imura H., Maeda M.;
RT   "A human T cell line established from a patient with Sezary syndrome.
RT   Application for assay of human interleukin 2 (IL-2).";
RL   J. Immunol. Methods 94:215-224(1986).
//
RX   PubMed=3263317; DOI=10.1016/0165-2478(88)90170-8;
RA   Maeda M., Noma T., Hama K., Honjo T.;
RT   "Application of a human T cell line derived from a Sezary syndrome
RT   patient for human interleukin 4 assay.";
RL   Immunol. Lett. 18:247-253(1988).
//
RX   PubMed=16242045; DOI=10.1186/1742-4690-2-64;
RA   Taniguchi Y., Nosaka K., Yasunaga J.-i., Maeda M., Mueller N.,
RA   Okayama A., Matsuoka M.;
RT   "Silencing of human T-cell leukemia virus type I gene transcription by
RT   epigenetic mechanisms.";
RL   Retrovirology 2:64.1-64.16(2005).
//
RX   PubMed=32210945; DOI=10.3389/fmicb.2020.00356;
RA   Maeda M., Tanabe-Shibuya J., Miyazato P., Masutani H., Yasunaga J.-i.,
RA   Usami K., Shimizu A., Matsuoka M.;
RT   "IL-2/IL-2 receptor pathway plays a crucial role in the growth and
RT   malignant transformation of HTLV-1-infected T cells to develop adult
RT   T-cell leukemia.";
RL   Front. Microbiol. 11:356.1-356.17(2020).
//